ARTICLE | Management Tracks
CSO Kilty replaces Weir as Sitryx CEO
Plus: Y-mAbs hires Peter Pfreundschuh as CFO, and updates from LIfT, 4P-Pharma and PepGen
July 3, 2024 1:03 AM UTC
Sitryx Therapeutics Ltd. chose CSO Iain Kilty to succeed CEO Neil Weir, who will become president while remaining on the board. Sitryx is developing autoimmune and inflammatory disease therapies that modulate immune cell metabolism. Kilty, who is a 22-year veteran of Pfizer Inc. (NYSE:PFE), will also join the board; a new CSO was not disclosed.
Peter Pfreundschuh became CFO at oncology company Y-mAbs Therapeutics Inc. (NASDAQ:YMAB). Pfreundschuh was CFO at Voyager Therapeutics Inc. (NASDAQ:VYGR). ...